Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

Eterna Therapeutics (ERNA)

Eterna Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:ERNA
DateTimeSourceHeadlineSymbolCompany
14/05/202422:14Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ERNAEterna Therapeutics Inc
10/05/202413:00GlobeNewswire Inc.Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on Development of Beta 2 Microglobulin-Knockout (B2M-KO) iMSC Line with Enhanced Immunosuppressive Activity and Stealthing Features that May Further Augment the Therapeutic Potential of MSCs iNASDAQ:ERNAEterna Therapeutics Inc
08/05/202414:31GlobeNewswire Inc.Eterna Therapeutics Announces Appointment of Mahendra Rao, PhD, to its Scientific Advisory BoardNASDAQ:ERNAEterna Therapeutics Inc
07/05/202413:00GlobeNewswire Inc.Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on the Development of a mRNA-Engineered iPSC Line which Mimics Native B2M Expression, via Targeted Insertion of HLA-E at the B2M LocusNASDAQ:ERNAEterna Therapeutics Inc
07/05/202413:00GlobeNewswire Inc.Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on Development of Beta 2 Microglobulin-Knockout (B2M-KO) iMSC Line with Enhanced Immunosuppressive Activity and Stealthing Features that May Further Augment the Therapeutic Potential of MSCs iNASDAQ:ERNAEterna Therapeutics Inc
20/02/202413:30GlobeNewswire Inc.Eterna Therapeutics Announces the Appointment of Peter Cicala, JD, to its Board of DirectorsNASDAQ:ERNAEterna Therapeutics Inc
16/02/202422:30Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:ERNAEterna Therapeutics Inc
16/02/202412:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ERNAEterna Therapeutics Inc
31/01/202412:05Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ERNAEterna Therapeutics Inc
24/01/202421:15Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:ERNAEterna Therapeutics Inc
23/01/202405:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ERNAEterna Therapeutics Inc
19/01/202421:16Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ERNAEterna Therapeutics Inc
19/01/202415:31Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ERNAEterna Therapeutics Inc
16/01/202421:16Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:ERNAEterna Therapeutics Inc
12/01/202421:49Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:ERNAEterna Therapeutics Inc
03/01/202422:02Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ERNAEterna Therapeutics Inc
03/01/202422:01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ERNAEterna Therapeutics Inc
03/01/202422:01Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:ERNAEterna Therapeutics Inc
03/01/202421:15GlobeNewswire Inc.Eterna Therapeutics Grants New President and CEO Sanjeev Luther Inducement Award Under Nasdaq Listing Rule 5635 (c)(4)NASDAQ:ERNAEterna Therapeutics Inc
22/12/202317:05Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:ERNAEterna Therapeutics Inc
20/12/202321:20Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ERNAEterna Therapeutics Inc
20/12/202321:15GlobeNewswire Inc.Eterna Therapeutics Names Sanjeev Luther as President and Chief Executive OfficerNASDAQ:ERNAEterna Therapeutics Inc
20/12/202320:24Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:ERNAEterna Therapeutics Inc
20/12/202315:05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ERNAEterna Therapeutics Inc
19/12/202302:38Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ERNAEterna Therapeutics Inc
14/12/202323:56GlobeNewswire Inc.Eterna Therapeutics Announces $9.2 Million Convertible Debt and Warrant FinancingNASDAQ:ERNAEterna Therapeutics Inc
14/12/202321:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ERNAEterna Therapeutics Inc
16/11/202321:16Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ERNAEterna Therapeutics Inc
13/11/202322:30Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:ERNAEterna Therapeutics Inc
13/11/202313:30Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ERNAEterna Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:ERNA

Your Recent History

Delayed Upgrade Clock